This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Benitec Biopharma Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Benitec Biopharma.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	35.0%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	26 Sep 2023

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

DB:BJ9 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	0	N/A	-22	N/A	1
6/30/2023	0	-20	-18	-18	N/A
3/31/2023	0	-20	-19	-19	N/A
12/31/2022	0	-19	-18	-18	N/A
9/30/2022	0	-18	-16	-16	N/A
6/30/2022	0	-18	-16	-16	N/A
3/31/2022	0	-17	-16	-16	N/A
12/31/2021	0	-18	-15	-15	N/A
9/30/2021	0	-16	-15	-15	N/A
6/30/2021	0	-14	-13	-13	N/A
3/31/2021	0	-13	-11	-11	N/A
12/31/2020	0	-11	-10	-10	N/A
9/30/2020	0	-10	-10	-9	N/A
6/30/2020	0	-8	-8	-8	N/A
3/31/2020	1	-7	-6	-6	N/A
12/31/2019	1	-6	N/A	N/A	N/A
9/30/2019	7	-2	2	2	N/A
6/30/2019	12	3	4	5	N/A
3/31/2019	12	2	4	4	N/A
12/31/2018	12	2	N/A	N/A	N/A
9/30/2018	8	-3	-3	-3	N/A
6/30/2018	3	-9	-7	-7	N/A
3/31/2018	4	-9	-7	-7	N/A
12/31/2017	6	-7	-6	-5	N/A
9/30/2017	5	-7	-5	-5	N/A
6/30/2017	9	-4	-7	-6	N/A
3/31/2017	7	-7	N/A	-6	N/A
12/31/2016	7	-8	N/A	-10	N/A
9/30/2016	7	-12	N/A	-13	N/A
6/30/2016	3	-18	N/A	-15	N/A
3/31/2016	3	-18	N/A	-17	N/A
12/31/2015	2	-16	N/A	-14	N/A
9/30/2015	2	-12	N/A	-10	N/A
6/30/2015	3	-9	N/A	-7	N/A
3/31/2015	3	-6	N/A	-5	N/A
12/31/2014	1	-7	N/A	-7	N/A
9/30/2014	1	-7	N/A	-8	N/A
6/30/2014	1	-7	N/A	-9	N/A
3/31/2014	1	-5	N/A	-8	N/A
12/31/2013	1	-3	N/A	-6	N/A
9/30/2013	1	-3	N/A	-5	N/A
6/30/2013	1	-3	N/A	-3	N/A
3/31/2013	1	-5	N/A	-3	N/A
12/31/2012	1	-6	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if BJ9's forecast earnings growth is above the savings rate (0.4%).

Winst versus markt: Insufficient data to determine if BJ9's earnings are forecast to grow faster than the German market

Hoge groeiwinsten: Insufficient data to determine if BJ9's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if BJ9's revenue is forecast to grow faster than the German market.

Hoge groei-inkomsten: Insufficient data to determine if BJ9's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if BJ9's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Benitec Biopharma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-Dose BB-301 in Phase 1b/2a Study

Benitec Biopharma Inc. Announces Appointment of Kishen Mehta to Its Board of Directors

Benitec Biopharma Inc. announced that it has received $40.000019 million in funding from a group of investors

Benitec Biopharma Inc. Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study

Benitec Biopharma Announces First Subject Dosed in Phase 1B/2A Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy

Benitec Biopharma Inc., Annual General Meeting, Dec 06, 2023

Benitec Biopharma Regains Compliance with the Bid Price Rule

Benitec Biopharma Provides Nasdaq Compliance Update

Insufficient new directors

Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program

Benitec Biopharma Inc., Annual General Meeting, Dec 07, 2022

Benitec Biopharma Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market for Compliance with the Minimum Bid Price Requirement

Full year 2022 earnings released

Third quarter 2022 earnings released: US$0.40 loss per share (vs US$0.82 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

First quarter 2022 earnings released: US$0.62 loss per share (vs US$2.45 loss in 1Q 2021)

Full year 2021 earnings released: US$3.23 loss per share (vs US$8.10 loss in FY 2020)

Benitec Biopharma Inc. Provides Overview of the BB-301 Phase 1B/2A Clinical Trial Design for 2022

Third quarter 2021 earnings released: US$0.82 loss per share (vs US$1.96 loss in 3Q 2020)

Benitec Biopharma Inc. Announces the Successful Results of the Interim Analysis of the Bb-301 Pilot Dosing Study

New 90-day high: €4.10

Second quarter 2021 earnings released: US$0.76 loss per share (vs US$2.00 loss in 2Q 2020)

New 90-day high: €2.68

First quarter 2021 earnings released: US$2.45 loss per share

New 90-day low: €2.42

New 90-day low: €3.98

Full year earnings released - €8.10 loss per share

New 90-day low - €5.80

Earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven